propensity score analysis

倾向得分分析
  • 文章类型: Journal Article
    英夫利昔单抗抢救急性重度溃疡性结肠炎(ASUC)患者的最佳方案仍存在争议。这项研究旨在比较中国ASUC患者的加速和标准英夫利昔单抗诱导,并探索危险因素和具体加速方案。
    回顾性地收集了在中国7个三级中心接受英夫利昔单抗作为抢救治疗的激素难治性ASUC患者的数据。在接受加速和标准英夫利昔单抗诱导的患者之间,使用针对潜在混杂因素的倾向评分校正,比较了结果,包括结肠切除术和临床缓解率(Mayo评分≤2,第14天时每个子评分≤1)。通过绘制有限的三次样条来探索剂量-反应关系。进行Logistic回归和Cox比例风险回归分析以确定不良结局的危险因素。还进行了系统评价和荟萃分析。
    共分析了76例患者:29例接受标准诱导,47例接受加速诱导。加速组的90天结肠切除率更高(17.8%vs0%,P=0.019)和较低的临床缓解率(27.7%vs65.5%,P=0.001)。在调整倾向评分和机构后,结肠切除术和临床缓解率差异无统计学意义(均P>0.05)。剂量-效应曲线显示,5天内,英夫利昔单抗累积剂量较高,结肠切除术风险降低,在28天内未观察到增加英夫利昔单抗累积剂量的改善。多变量逻辑回归分析显示,英夫利昔单抗开始时C反应蛋白>10mg/L(比值比=5.00,95%置信区间:1.27-24.34)是无临床缓解的独立危险因素。Meta分析也显示3个月时结肠切除率无显著差异(P=0.54)。
    调整混杂因素后,在ASUC患者中,加速和标准英夫利昔单抗诱导的结肠切除术或临床缓解率无显著差异.在5天内早期给予强化剂量可能是有益的。英夫利昔单抗开始时C反应蛋白升高表明需要强化治疗。
    UNASSIGNED: The optimal regimen of infliximab salvage in acute severe ulcerative colitis (ASUC) patients remains controversial. This study aimed to compare accelerated and standard infliximab induction in Chinese ASUC patients, and to explore risk factors and concrete accelerated regimens for them.
    UNASSIGNED: Data were retrospectively collected from steroid-refractory ASUC patients receiving infliximab as rescue therapy at seven tertiary centers across China. Outcomes including colectomy and clinical remission (Mayo score ≤ 2 and every subscore ≤ 1 at Day 14) rates were compared between patients receiving accelerated and standard infliximab induction using propensity score adjustment for potential confounders. The dose-response relationship was explored by plotting restricted cubic splines. Logistic regression and Cox proportional hazards regression analyses were performed to determine risk factors for adverse outcomes. A systematic review and meta-analysis was also performed.
    UNASSIGNED: A total of 76 patients were analysed: 29 received standard and 47 received accelerated induction. The accelerated group had a higher 90-day colectomy rate (17.8% vs 0%, P = 0.019) and lower clinical remission rate (27.7% vs 65.5%, P = 0.001). After adjusting for propensity score and institution, there was no significant difference in colectomy or clinical remission rates (both P > 0.05). Dose-effect curves showed decreased colectomy hazard with higher cumulative infliximab dosage within 5 days, with no improvement observed for increasing cumulative infliximab dosage within 28 days. Multivariate logistic regression analyses revealed C-reactive protein of >10 mg/L at infliximab initiation (odds ratio = 5.00, 95% confidence interval: 1.27-24.34) as an independent risk factor for no clinical remission. Meta-analysis also revealed no significant difference in colectomy rates at 3 months (P = 0.54).
    UNASSIGNED: After adjusting for confounders, there were no significant differences in colectomy or clinical remission rates between accelerated and standard infliximab induction among ASUC patients. Early administration of an intensified dosage within 5 days may be beneficial. Elevated C-reactive protein at infliximab initiation indicated need for intensive treatment.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    背景:我们调查了具有病理高危因素的I期肺腺癌患者辅助治疗的真实世界疗效。
    方法:研究参与者于2016年11月1日和2020年12月31日入组。通过倾向评分匹配来平衡临床偏倚。通过Kaplan-Meier分析比较无病生存(DFS)结果。Cox比例风险回归用于确定生存相关因素。p≤0.05为统计学意义的阈值。
    结果:总共454名患者,其中134人(29.5%)接受了辅助治疗,参加了这项研究。接受辅助治疗的患者中有118例与非治疗患者非常匹配。治疗组的预后结果明显优于非治疗组,PSM后的Kaplan-Meier分析显示。靶向治疗组和化疗组在预防复发或转移方面差异不显著。发现辅助治疗是积极的预后因素,肿瘤大小和实体生长模式均为阴性.
    结论:辅助治疗可显著改善具有高危因素的I期肺腺癌患者的DFS。应该进行更大的前瞻性临床试验来验证我们的发现。
    BACKGROUND: We investigated the real-world efficacy of adjuvant therapy for stage I lung adenocarcinoma patients with pathological high-risk factors.
    METHODS: Study participants were enrolled from November 1, 2016 and December 31, 2020. Clinical bias was balanced by propensity score matching. Disease-free survival (DFS) outcomes were compared by Kaplan-Meier analysis. The Cox proportional hazards regression was used to identify survival-associated factors. p ≤ 0.05 was the threshold for statistical significance.
    RESULTS: A total of 454 patients, among whom 134 (29.5%) underwent adjuvant therapy, were enrolled in this study. One hundred and eighteen of the patients who underwent adjuvant therapy were well matched with non-treatment patients. Prognostic outcomes of the treatment group were significantly better than those of the non-treatment group, as revealed by Kaplan-Meier analysis after PSM. Differences in prevention of recurrence or metastasis between the targeted therapy and chemotherapy groups were insignificant. Adjuvant therapy was found to be positive prognostic factors, tumor size and solid growth patterns were negative.
    CONCLUSIONS: Adjuvant therapy significantly improved the DFS for stage I lung adenocarcinoma patients with high-risk factors. Larger prospective clinical trials should be performed to verify our findings.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    营养不足与抗结核(TB)治疗反应和结核病治疗结果之间的因果关系研究不足。
    为了评估坎帕拉的再治疗药物敏感型结核病患者中营养不足对治疗成功和痰涂片转换的影响,乌干达。
    我们在2012年至2022年在坎帕拉接受治疗的年龄≥15岁的再治疗药物易感结核病患者中使用倾向评分加权进行了一项准实验研究。主要暴露是在结核病诊断时使用中上臂围评估的营养不足。主要结果是治疗成功,定义为6个月时治愈或治疗完成。痰涂片转换是次要结果,并在第2、5和6个月时测量痰涂片状态从阳性到阴性的变化。我们使用具有稳健误差方差的倾向评分加权修正泊松回归模型估计营养不足对结局的因果影响。
    在605名参与者中,432(71.4%)为男性,215人(35.5%)年龄在25-34岁之间,427例(70.6%)有细菌学证实的肺结核,133例(22.0%)营养不良,398例(65.8%)治疗成功。在细菌学证实为肺结核的参与者中,232(59.0%),327(59.3%),分别在第2、5和6个月时,有360例(97.6%)实现了痰涂片转换。营养不良降低了治疗成功率(RR0.42,95%CI0.32-0.55)以及第2个月(RR0.45,95%CI0.42-0.49)和第5个月(RR0.46,95%CI0.43-0.51)的痰涂片转换,但不是第6个月(RR0.99,95%CI0.97-1.02)。
    营养不良会对治疗结果产生负面影响。因此,营养评估应该是结核病护理的一个组成部分,向营养不良者提供营养咨询和支持,以优化他们的结核病治疗反应和结局。
    UNASSIGNED: The causal relationship between undernutrition and response to anti-tuberculosis (TB) treatment and TB treatment outcomes among people with retreatment TB is understudied.
    UNASSIGNED: To evaluate the effect of undernutrition on treatment success and sputum smear conversion among people with retreatment drug-susceptible TB in Kampala, Uganda.
    UNASSIGNED: We conducted a quasi-experimental study utilizing propensity score weighting among people with retreatment drug-susceptible TB aged ≥ 15 years treated between 2012 and 2022 in Kampala. The primary exposure was undernutrition assessed using the mid-upper arm circumference at the time of TB diagnosis. The primary outcome was treatment success defined as cure or treatment completion at month 6. Sputum smear conversion was the secondary outcome and was measured as a change in sputum smear status from positive to negative at months 2, 5, and 6. We estimated the causal effect of undernutrition on the outcomes using a propensity-score weighted modified Poisson regression model with robust error variance.
    UNASSIGNED: Of the 605 participants, 432 (71.4 %) were male, 215 (35.5 %) were aged 25-34 years, 427 (70.6 %) had bacteriologically confirmed pulmonary TB, 133 (22.0 %) were undernourished and 398 (65.8 %) achieved treatment success. Of participants with bacteriologically confirmed pulmonary TB, 232 (59.0 %), 327 (59.3 %), and 360 (97.6 %) achieved sputum smear conversion at months 2, 5, and 6, respectively. Undernutrition reduced treatment success (RR 0.42, 95 % CI 0.32-0.55) as well as sputum smear conversion at months 2 (RR 0.45, 95 % CI 0.42-0.49) and 5 (RR 0.46, 95 % CI 0.43-0.51) but not month 6 (RR 0.99, 95 % CI 0.97-1.02).
    UNASSIGNED: Undernutrition negatively impacts treatment outcomes. Therefore, nutritional assessment should be an integral component of TB care, with nutritional counseling and support offered to those undernourished to optimize their TB treatment response and outcomes.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    目的我们的目的是比较内镜切除与开放手术联合放疗治疗局部晚期鼻窦恶性肿瘤(SNMs)的长期疗效。方法回顾性分析1999年1月至2016年12月在本中心接受手术(内镜下或开放手术)联合放疗的持续鼻窦鳞癌和腺癌患者的资料。进行与倾向评分的1:1匹配。总生存期(OS),无进展生存期(PFS),评估局部复发率(LRR)。结果我们确定了267名合格患者,匹配后纳入90例:内镜组45例,开放组45例。中位随访时间为87个月。在内窥镜组中,84.4%的患者接受了调强放疗(IMRT),平均总肿瘤体积(GTV)剂量为68.28Gy;在开放手术组中,64.4%的患者接受了IMRT,平均GTV剂量为64Gy.5年OS,PFS,内镜组LRR分别为69.9、58.6和24.5%,开放手术组为64.6、54.4和31.8%,分别。多因素回归分析显示,手术入路与较低的OS无关,PFS,或LRR。内镜组术后总并发症为13%,而开放组的21.7%。结论对于局部晚期SNM患者,内镜下微创切除术,结合更高的辐射剂量和新的辐射技术,如IMRT,与开放手术联合放疗的生存结局相似.
    Objective  Our objective was to compare the long-term outcomes of endoscopic resection versus open surgery in combination with radiotherapy for locally advanced sinonasal malignancies (SNMs). Methods  Data for continuous patients with sinonasal squamous cell carcinoma and adenocarcinoma who received surgery (endoscopic or open surgery) combined with radiotherapy in our center between January 1999 and December 2016 were retrospectively reviewed. A 1:1 matching with propensity scores was performed. Overall survival (OS), progression-free survival (PFS), and local recurrence rate (LRR) were evaluated. Results  We identified 267 eligible patients, 90 of whom were included after matching: 45 patients in the endoscopy group and 45 in the open group. The median follow-up time was 87 months. In the endoscopic group, 84.4% of patients received intensity-modulated radiotherapy (IMRT), with a mean gross tumor volume (GTV) dose of 68.28 Gy; in the open surgery group, 64.4% of patients received IMRT, with a mean GTV dose of 64 Gy. The 5-year OS, PFS, and LRR were 69.9, 58.6, and 24.5% in the endoscopic group and 64.6, 54.4, and 31.8% in the open surgery group, respectively. Multivariable regression analysis revealed that the surgical approach was not associated with lower OS, PFS, or LRR. The overall postoperative complications were 13% in the endoscopic group, while 21.7% in the open group. Conclusion  For patients with locally advanced SNMs, minimally invasive endoscopic resection, in combination with a higher radiation dose and new radiation techniques such as IMRT, yields survival outcomes similar to those of open surgery in combination with radiotherapy.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    红细胞分布宽度(RDW)和血清钙(Ca)水平是急性心肌梗死(AMI)患者住院死亡率的预测因子。然而,其敏感性和特异性有限。因此,本研究旨在确定入院时获得的RDW与Ca比值(RCR)是否可用于预测AMI患者的住院死亡率.
    这项回顾性队列研究从密集IV医疗信息市场(MIMIC-IV)数据库中提取了通过倾向评分匹配(PSM)招募的2,910名AMI患者的临床信息。使用多变量逻辑模型和三种PSM方法评估预后值。基于分层变量和性别之间的相互作用进行分析,年龄,种族,贫血,肾脏疾病,经皮冠状动脉介入治疗(PCI),冠状动脉旁路移植术(CABG),心房颤动,充血性心力衰竭,痴呆症,糖尿病,截瘫,高血压,脑血管疾病,和序贯器官衰竭评估(SOFA)评分。
    共分析了4105例ICU收治的AMI患者。住院死亡率RCR的最佳临界值为1.685。进行PSM以识别1,455对(2,910)得分匹配的患者,几乎所有变量都表现出平衡差异。患者的平均年龄为72岁(范围,63-82岁)和60.9%为男性。院内死亡发生率的风险随着RCR水平的增加而增加。在调整了混杂因素后,在PSM队列中,与低RCR相关的风险比相比,高RCR的院内死亡率发生率为1.75[95%置信区间(CI):1.60~1.94,P=0.0113].在加权队列中,高RCR也与住院死亡率有关[比值比(OR)=1.76,95%CI:1.62-1.94,P=0.0129]。三组的RCR评估显示,与调整模型中的RCR患者相比,高RCR患者的院内死亡率更高(OR=3.04;95%CI,2.22-4.16;P<0.0001)。在敏感性分析中,原始组和加权组均显示相似的结果.
    入院时的RCR可用于预测ICU住院AMI患者的住院死亡率。
    UNASSIGNED: Red cell distribution width (RDW) and serum calcium (Ca) levels are predictors of in-hospital mortality in acute myocardial infarction (AMI) patients. However, their sensitivity and specificity are limited. Therefore, this study aimed to determine whether the RDW to Ca ratio (RCR) acquired on admission can be used to predict the in-hospital mortality of AMI patients.
    UNASSIGNED: This retrospective cohort study extracted clinical information from the Medical Information Market for Intensive IV (MIMIC-IV) database on 2,910 AMI patients enrolled via propensity score matching (PSM). Prognostic values were assessed using a multivariate logistic model and three PSM approaches. Analysis was performed based on stratified variables and interactions among sex, age, ethnicity, anemia, renal disease, percutaneous transluminal coronary intervention (PCI), coronary artery bypass grafting (CABG), atrial fibrillation, congestive heart failure, dementia, diabetes, paraplegia, hypertension, cerebrovascular disease, and Sequential Organ Failure Assessment (SOFA) score.
    UNASSIGNED: A total of 4,105 ICU-admitted AMI patients were analyzed. The optimal cut-off value of the RCR for in-hospital mortality was 1.685. The PSM was performed to identify 1,455 pairs (2,910) of score-matched patients, with balanced differences exhibited for nearly all variables.The patients\' median age was 72 years (range, 63-82 years) and 60.9% were male. The risk of in-hospital mortality incidence increased with increasing RCR levels. After adjusting for confounders, the risk ratio for the incidence of in-hospital mortality for high RCR was 1.75 [95% confidence interval (CI): 1.60-1.94, P = 0.0113] compared to that associated with low RCR in the PSM cohort. High RCR was also substantially implicated in in-hospital mortality incidence in the weighted cohorts [odds ratio (OR) = 1.76, 95% CI: 1.62-1.94, P = 0.0129]. Assessment of RCR in three groups showed that patients with high RCR also had a higher risk of in-hospital mortality (OR = 3.04; 95% CI, 2.22-4.16; P < 0.0001) than in patients with RCR in the adjusted model. In the sensitivity analysis, both the original and weighted groups showed similar results.
    UNASSIGNED: The RCR at admission may be useful for predicting in-hospital mortality in ICU-admitted AMI patients.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    背景:这项研究调查了接受痴呆症诊断如何通过种族和民族影响社会关系。
    方法:使用来自健康与退休研究的数据(10波;7,159观察),使用Gianattasio-Power评分(91%的准确率)预测70岁及以上的成年人患有痴呆症,这项研究评估了社会支持的变化,订婚,和痴呆症诊断后的网络。我们利用准实验方法来评估种族/种族的治疗效果和亚组分析。
    结果:诊断标签显着增加了获得社会支持的可能性,但降低了社会参与度和社交网络的一种衡量标准。除了一些例外,不同种族和民族的结果相似。
    结论:结果表明,在假定痴呆的老年人中,被医生诊断可能以寻求支持和社会退缩的方式影响社会关系。这表明,在诊断时讨论服务和支持对医疗保健专业人员很重要。
    This study examines how receiving a dementia diagnosis influences social relationships by race and ethnicity.
    Using data from the Health and Retirement Study (10 waves; 7,159 observations) of adults 70 years and older predicted to have dementia using Gianattasio-Power scores (91% accuracy), this study assessed changes in social support, engagement, and networks after a dementia diagnosis. We utilized quasi-experimental methods to estimate treatment effects and subgroup analyses by race/ethnicity.
    A diagnostic label significantly increased the likelihood of gaining social support but reduced social engagement and one measure of social networks. With some exceptions, the results were similar by race and ethnicity.
    Results suggest that among older adults with assumed dementia, being diagnosed by a doctor may influence social relationships in both support-seeking and socially withdrawn ways. This suggests that discussing services and supports at the time of diagnosis is important for healthcare professionals.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    中介分析通过更精确的淋巴结(LN)状态评估前哨淋巴结(SLN)定位对结肠癌患者预后和生存的保护作用。
    高达20%的结阴性结肠癌患者出现疾病复发。常规的组织病理学LN检查可能仅限于描述LN的真实转移负担。
    前瞻性收集312例I期和II期结肠癌患者的数据。使用术中SLN作图,对SLN进行多级切片和免疫组织化学染色或常规技术,对患者进行分期。使用Cox回归和中介分析评估SLN映射对检测真正淋巴结阴性患者的价值。
    对143例患者进行SLN作图。在SLN定位分期的13例(9.1%)患者和常规分期的27例(16%)患者中观察到疾病复发。五年总生存率(OS)为82.7%(95%置信区间[CI],76.5-89.4%)与SLN作图相比,为65.8%(95%CI,58.8-73.7%)。SLN映射的5年癌症特异性生存率(CSS)为95.1%(95%CI,91.3-99.0%),而92.5%(95%CI,88.0-97.2%)。SLN映射的节点阴性分期与显著更好的OS相关(风险比[HR],0.64;95%CI,0.56-0.72;P<0.001)和CSS(HR,多变量分析为0.49;95%CI,0.39-0.61;P<0.001)。中介分析证实了SLN映射对OS(HR,0.78;95%CI,0.52-0.96;P<0.01)和无病生存期(DFS)(HR,0.75;95%CI,0.48-0.89;P<0.01)。
    通过具有多级切片的SLN映射执行的分期比常规分期提供更准确的结果。在OS和DFS中观察到的临床相关和统计学上显著的益处通过通过SLN映射更准确地检测阳性LN来解释。
    UNASSIGNED: Mediation analysis to assess the protective impact of sentinel lymph node (SLN) mapping on prognosis and survival of patients with colon cancer through a more precise evaluation of the lymph node (LN) status.
    UNASSIGNED: Up to 20% of patients with node-negative colon cancer develop disease recurrence. Conventional histopathological LN examination may be limited in describing the real metastatic burden of LN.
    UNASSIGNED: Data of 312 patients with stage I & II colon cancer was collected prospectively. Patients were either staged using intraoperative SLN mapping with multilevel sectioning and immunohistochemical staining of the SLN or conventional techniques. The value of the SLN mapping for the detection of truly node-negative patients was assessed using Cox regression and mediation analysis.
    UNASSIGNED: SLN mapping was performed in 143 patients. Disease recurrence was observed in 13 (9.1%) patients staged with SLN mapping and in 27 (16%) staged conventionally. Five-year overall survival (OS) rate was 82.7% (95% confidence interval [CI], 76.5-89.4%) with SLN mapping compared with 65.8% (95% CI, 58.8-73.7%). Five-year cancer-specific survival (CSS) was 95.1% (95% CI, 91.3-99.0%) with SLN mapping compared with 92.5% (95% CI, 88.0-97.2%). Node-negative staging with SLN mapping was associated with significantly better OS (hazard ratio [HR], 0.64; 95% CI, 0.56-0.72; P < 0.001) and CSS (HR, 0.49; 95% CI, 0.39-0.61; P < 0.001) in multivariate analysis. Mediation analysis confirmed a direct protective effect of SLN mapping on OS (HR, 0.78; 95% CI, 0.52-0.96; P < 0.01) and disease-free survival (DFS) (HR, 0.75; 95% CI, 0.48-0.89; P < 0.01).
    UNASSIGNED: Staging performed by SLN mapping with multilevel sectioning provides more accurate results than conventional staging. The observed clinically relevant and statistically significant benefit in OS and DFS is explained by a more accurate detection of positive LN by SLN mapping.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    背景:在不同的Forrest分类中,联合治疗是否比肾上腺素单药治疗具有更高的止血功效尚不清楚。这项研究旨在比较基于不同Forrest分类的肾上腺素注射液单药治疗(MT)和联合治疗(CT)之间的止血效果。
    方法:我们回顾性分析了2014年3月至2022年6月在我们中心接受内镜下肾上腺素注射或肾上腺素注射联合第二治疗的消化性溃疡出血(PUB)患者。将患者分为MT组和CT组。随后,我们进行了倾向评分匹配分析(PSM),并通过分层分析根据Forrest分类计算再出血率.
    结果:总体而言,纳入符合纳入标准的605例患者,在PSM之后,纳入CT组和MT组各173例患者。对于具有非出血可见血管(FIIa)的PUB患者,PSM后第3、7、14和30天的再出血率为8.8%,17.5%,19.3%,在MT集团中占19.3%,分别,比率为0%,4.1%,5.5%,CT组为5.5%,分别,在第3、7、14和30天观察到两组之间存在显着差异(分别为P=0.015,P=0.011,P=0.014和P=0.014)。然而,对于有渗出性出血(FIb)的PUB患者,PSM后第3、7、14和30天的再出血率为14.9%,16.2%,17.6%,在MT组中占17.6%,分别,率为13.2%,14.7%,14.7%,CT组为16.2%,分别,到第3、7、14和30天,两组之间没有显着差异(P=0.78,P=0.804,P=0.644和P=0.825)。
    结论:联合治疗对PUB患者可见血管(FIIa)溃疡的止血效果优于单用肾上腺素注射液。然而,对于有渗血(FIb)溃疡的PUB患者,肾上腺素单药治疗与联合治疗同样有效。
    Whether combination therapy has higher hemostatic efficacy than epinephrine injection monotherapy in different Forrest classifications is not clear. This study aimed to compare hemostatic efficacy between epinephrine injection monotherapy (MT) and combination therapy (CT) based on different Forrest classifications.
    We retrospectively analyzed peptic ulcer bleeding (PUB) patients who underwent endoscopic epinephrine injections or epinephrine injections combined with a second therapy between March 2014 and June 2022 in our center, and the patients were divided into MT group or CT group. Subsequently, a propensity score matching analysis (PSM) was performed and rebleeding rates were calculated according to Forrest classifications via a stratified analysis.
    Overall, 605 patients who met the inclusion criteria were included, and after PSM, 173 patients in each of the CT and MT groups were included. For PUB patients with nonbleeding visible vessels (FIIa), the rebleeding rates by Days 3, 7, 14, and 30 after PSM were 8.8%, 17.5%, 19.3%, and 19.3% in the MT group, respectively, and rates were 0%, 4.1%, 5.5%, and 5.5% in the CT group, respectively, with significant differences observed between the two groups by Days 3, 7, 14, and 30 (P = 0.015, P = 0.011, P = 0.014, and P = 0.014, respectively). However, for PUB patients with oozing bleeding (FIb), the rebleeding rates by Days 3, 7, 14, and 30 after PSM were 14.9%, 16.2%, 17.6%, and 17.6% in the MT group, respectively, and rates were 13.2%, 14.7%, 14.7%, and 16.2% in the CT group, respectively, with no significant differences observed between the two groups by Days 3, 7, 14, and 30 (P = 0.78, P = 0.804, P = 0.644 and P = 0.825).
    Combined therapy has higher hemostatic efficacy than epinephrine injection monotherapy for PUB patients with visible blood vessel (FIIa) ulcers. However, epinephrine injection monotherapy is equally as effective as combined therapy for PUB patients with oozing blood (FIb) ulcers.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    全面评估和验证外周血白细胞(PBLs)中胰岛素样生长因子2(IGF2)基因甲基化与结直肠癌(CRC)风险和预后之间的关系。
    PBLs中IGF2甲基化与CRC风险之间的关联最初在病例对照研究中进行评估,然后在嵌套病例对照研究和双胞胎病例对照研究中进行验证。分别。同时,最初的CRC患者队列用于评估IGF2甲基化对CRC预后的影响,然后在EPIC-意大利CRC队列和TCGA数据集上验证了这一发现.进行了倾向评分(PS)分析,以控制混杂因素,我们进行了广泛的敏感性分析,以评估我们研究结果的稳健性.
    在初始研究中,PBLIGF2高甲基化与CRC风险增加相关(ORPS调整,2.57,95%CI:1.65~4.03,P<0.0001),并使用两个独立的外部数据集(ORPS调整,2.21,95%CI:1.28至3.81,P=0.0042,经ORPS调整,10.65,95%CI:分别为1.26~89.71,P=0.0295)。与IGF2低甲基化的患者相比,PBLs中IGF2高甲基化的CRC患者的总体生存率显着提高(HRPS调整,0.47,95%CI:0.29~0.76,P=0.0019)。在EPIC-意大利CRC队列中也观察到了预后特征,虽然HR没有达到统计学意义(HRPS校正,0.69,95%CI:0.37~1.27,P=0.2359)。
    IGF2超甲基化可作为潜在的基于血液的预测性生物标志物,用于鉴定处于发展为CRC的高风险的个体和CRC预后。
    UNASSIGNED: To comprehensively assess and validate the associations between insulin-like growth factor 2 (IGF2) gene methylation in peripheral blood leukocytes (PBLs) and colorectal cancer (CRC) risk and prognosis.
    UNASSIGNED: The association between IGF2 methylation in PBLs and CRC risk was initially evaluated in a case-control study and then validated in a nested case-control study and a twins\' case-control study, respectively. Meanwhile, an initial CRC patient cohort was used to assess the effect of IGF2 methylation on CRC prognosis and then the finding was validated in the EPIC-Italy CRC cohort and TCGA datasets. A propensity score (PS) analysis was performed to control for confounders, and extensive sensitivity analyses were performed to assess the robustness of our findings.
    UNASSIGNED: PBL IGF2 hypermethylation was associated with an increased risk of CRC in the initial study (ORPS-adjusted, 2.57, 95% CI: 1.65 to 4.03, P<0.0001), and this association was validated using two independent external datasets (ORPS-adjusted, 2.21, 95% CI: 1.28 to 3.81, P=0.0042 and ORPS-adjusted, 10.65, 95% CI: 1.26 to 89.71, P=0.0295, respectively). CRC patients with IGF2 hypermethylation in PBLs had significantly improved overall survival compared to those patients with IGF2 hypomethylation (HRPS-adjusted, 0.47, 95% CI: 0.29 to 0.76, P=0.0019). The prognostic signature was also observed in the EPIC-Italy CRC cohort, although the HR did not reach statistical significance (HRPS-adjusted, 0.69, 95% CI: 0.37 to 1.27, P=0.2359).
    UNASSIGNED: IGF2 hypermethylation may serve as a potential blood-based predictive biomarker for the identification of individuals at high risk of developing CRC and for CRC prognosis.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    目的:我们先前已经证明,长时间使用青光眼药物与ab间小梁切开术(µTLO)的不良手术结果相关。鉴于几乎所有类型的青光眼滴眼液都可以增强通过葡萄膜巩膜途径的引流或减少房水的产生,我们假设长期使用这些药物可能会导致常规途径的废用萎缩.相比之下,ripasudil增加了常规的流出,并最终显示出µTLO的有利结果。本研究旨在评估使用rapasudil对μTLO结果的影响。
    方法:回顾性分析218例接受μTLO治疗的患者的病历。我们通过使用倾向得分匹配比较了ripasudil用户与非用户之间的1年结果。我们将协变量设置为年龄,性别,青光眼类型,术前眼压(IOP),视野测试的平均偏差值,有无伴随白内障手术,小梁网切口范围,是否存在任何青光眼药物,除了利帕舒地尔和青光眼药物治疗的持续时间。成功定义为术后IOP在5和21mmHg之间,从基线眼压降低≥20%,术后1年无额外青光眼手术。
    结果:57例患者均被分配给rapasudil使用者或非使用者。rapasudil用户的1年成功率为74%,非用户为51%(p=0.01)。Kaplan-Meier存活曲线还显示rapasudil使用者具有较高的生存分布(p=0.01)。
    结论:服用雷帕舒地尔的患者表现出良好的µTLO1年结局。
    OBJECTIVE: We have previously demonstrated that prolonged use of glaucoma medications was associated with a poor surgical outcome of ab interno trabeculotomy (µTLO). Given that almost all types of glaucoma eye drop either enhance the drainage through the uveoscleral pathway or reduce aqueous humor production, we hypothesized that prolonged use of these medications might cause disuse atrophy of the conventional pathway. In contrast, ripasudil increases the conventional outflow and eventually shows a favorable outcome of µTLO. This study aimed to evaluate the effect of ripasudil use on µTLO outcomes.
    METHODS: The medical charts of 218 patients who underwent µTLO were analyzed retrospectively. We compared the 1-year outcome between ripasudil users versus nonusers by using propensity score matching. We set the covariates as age, sex, glaucoma types, preoperative intraocular pressure (IOP), the mean deviation values of visual field tests, the presence or absence of concomitant cataract surgery, trabecular meshwork incision range, the presence or absence of any glaucoma medication except ripasudil and duration of glaucoma medical therapy. Success was defined as a postoperative IOP between 5 and 21 mmHg, a ≥ 20% IOP reduction from baseline, and no additional glaucoma surgery at postoperative 1 year.
    RESULTS: Fifty-seven patients each were allocated to the ripasudil users or nonusers. The 1-year success rates were 74% in ripasudil users and 51% in nonusers (p = 0.01). Kaplan‒Meier survival curves also showed that the ripasudil users had a higher survival distribution (p = 0.01).
    CONCLUSIONS: The patients who took ripasudil showed a favorable 1-year outcome of µTLO.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

公众号